Background. Safety and immunogenicity of heat-treated zoster vaccine (ZV HT ) were assessed in immunocompromised adults.
The incidence and severity of herpes zoster (HZ) are increased in immunocompromised populations with impaired cell-mediated immunity. Patients receiving chemotherapy for a hematologic malignancy (HM) or solid tumor malignancy (STM), undergoing a hematopoietic stem-cell transplant (HCT), or infected with human immunodeficiency virus (HIV) all have higher incidences of HZ than healthy persons [1] . Compared to the general population where the incidence of HZ is 2-5 cases/1000 person-years, the respective incidences of HZ in patients receiving treatment for a STM, given chemotherapy for a HM, infected with HIV, or undergoing HCT are 15-80, 25-100, 20-100, and 200 cases/ 1000 person-years [2] [3] [4] [5] [6] [7] [8] [9] . These immunocompromised populations also experience significant morbidity and occasional mortality from complications associated with reactivation of the varicella-zoster virus (VZV), including post-herpetic neuralgia (PHN), secondary bacterial infections, and disseminated VZV infection.
Currently, a live attenuated zoster vaccine (ZOSTAVAX™; Merck & Co., Inc., Whitehouse Station, NJ) is approved for prevention of HZ in immunocompetent individuals ≥50 years [10] . In large placebo-controlled trials, vaccination with the live attenuated zoster vaccine demonstrated an excellent safety profile and was associated with a reduction of the incidence of HZ by 51% to 70% and a reduction of the incidence of PHN by approximately 66% [11, 12] . Over 11 million doses of zoster vaccine have been administered; the vaccine has a favorable safety profile and rashes testing positive for the vaccine strain by polymerase chain reaction (PCR) occur very rarely. However, the live attenuated zoster vaccine is contraindicated in immunocompromised populations, which leave this highrisk population with no means of enhancing immunity against this virus.
Initial studies using a heat-treated inactivated Oka/Merck varicella vaccine showed the vaccine was generally safe, reconstituted T-cell immunity against VZV, and reduced morbidity from VZV reactivation in HCT recipients [13, 14] . Based on these favorable results, we undertook this study to further evaluate the safety and immunogenicity of a heat-treated VZV vaccine (ZV HT ) in a diverse population of immunocompromised patients, including patients receiving therapy for a STM or HM, HIV-infected patients, and individuals undergoing HCT.
METHODS

Study Design
This randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and immunogenicity of ZV HT in immunocompromised adults was conducted between November 2007 and January 2010 in accordance with the ethical principles of the Declaration of Helsinki and the principles of current Good Clinical Practices. The study protocol and amendments were approved by local or central institutional review boards. All patients provided written informed consent.
Randomization was stratified by the underlying disease (Table 1) . Patients were randomized to receive either ZV HT (n = 262) or placebo (n = 79), both of which were given as a 4-dose regimen (Figure 1 ). For HCT recipients, dose 1 was administered approximately 30 days prior to a scheduled autologous or allogeneic HCT and doses 2 through 4 were administered at 30, 60, and 90 days post-HCT. HIV-infected patients and those with HM not receiving chemotherapy received dose 1 at the time of enrollment and doses 2 through 4 at approximately 30-day intervals. For patients with STM or HM receiving chemotherapy, study vaccine was administered approximately 7 days before any chemotherapy cycle with approximately 30 days between doses.
The sizes of the underlying disease groups (STM, HM, and HIV) were chosen to provide initial immunogenicity and safety data prior to initiating larger phase III studies and provided 76% power to detect a VZV interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT) geometric mean fold-rise (GMFR) (lower bound of 90% confidence interval [CI] > 1.0) if the true GMFR was 2.0-fold and 83% power to detect a glycoprotein enzyme-linked immunosorbent assay (gpELISA) GMFR if the true GMFR was 1.5-fold. Autologous and allogeneic HCT populations were included in this study to provide additional safety data and experience with immunogenicity assays not used in initial studies [13, 14] .
Study Population
Immunocompromised patients ≥18 years with at least a 1-year life expectancy and a history of varicella or residence in a VZVendemic area for ≥30 years were eligible for the study. Immunocompromised populations included in this study were (1) individuals with STM receiving chemotherapy, (2) individuals with HM, (3) HIV-infected individuals with a baseline CD4 + cell count ≤200 cells/mm 3 , and (4) autologous or allogeneic HCT recipients (Table 1) .
Patients were excluded if they had a history of hypersensitivity to ZV HT vaccine components; a history of HZ within 1 year of enrollment; a prior history of receipt of any VZV vaccine; were pregnant or expecting to conceive from the period of time of 2 weeks prior to vaccination through 6 months after the last vaccination; or had received, or were scheduled to receive, a live virus vaccine in the period from 4 weeks prior to dose 1 through 28 days post-dose 4.
Patients With STM Receiving Chemotherapy
Patients with STM diagnosed ≤2 years prior to enrollment were included if they were undergoing frontline cytotoxic chemotherapy (including biologic treatments) for primary breast, colorectal, lung, or ovarian cancer. Study candidates with STM were excluded if they had central nervous system (CNS) metastasis, recurrence of cancer, or if they required modification of planned chemotherapy regimen because of intolerance to a chemotherapeutic agent. Patients who received blood products, immunostimulants, or immunosuppressive monoclonal antibody biologic treatments were excluded.
Patients With HM
Patients with HM (leukemia, lymphoma, or multiple myeloma) were included if they were receiving a chemotherapeutic regimen without rituximab or received the last dose of rituximab ≥3 months prior to study enrollment. Individuals ≥50 years with chronic lymphocytic leukemia (CLL) or active lymphoma but not receiving chemotherapy and not likely to undergo HCT during the study period were also included. Patients with HM were excluded from the study if they had CNS metastasis, an underlying cancer (other than Hodgkin's 
HCT Recipients
Patients undergoing HCT were included if they were scheduled to undergo an autologous HCT for the treatment of leukemia, lymphoma, or other cancer or receive an allogeneic HCT for any reason within 60 days of enrollment. Patients undergoing HCT were excluded if they had more than 2 relapses of their underlying cancer (excluding Hodgkin's lymphoma) or were expected to undergo a tandem transplant procedure.
Study Vaccine Description
The lyophilized ZV HT vaccine (4.8 UAg/dose) and placebo (vaccine stabilizer for ZV HT with no virus antigen) were supplied to the study centers in 3.0-mL single-dose vials and refrigerated at 2°C-8°C (or colder). Both study products were reconstituted with sterile diluent immediately prior to administration and were indistinguishable from each other. All patients received a total of 4 0.65-mL subcutaneous injections of either ZV HT or placebo according to the predefined dosing schedule. Four vaccine doses were administered in this study because of favorable safety and efficacy data obtained with a 4-dose vaccine regimen in a pilot study of patients undergoing autologous HCT [14] . The number of vaccine doses that may confer protection from HZ in the STM, HM, and HIV populations is not known.
Safety Surveillance
The safety and tolerability assessment in each of the immunocompromised populations was based on adverse experiences (AEs) reported from the first dose of vaccine through 28 days post-dose 4. Throughout this period, daily oral temperature readings, injection-site reactions, and systemic AEs were recorded on a vaccination report card (VRC). Patients recorded injection-site AEs (redness, swelling, and pain/tenderness) for 5 days after each vaccination on the VRC.
Patients who developed suspected varicella/varicella-like or HZ/HZ-like rashes during the follow-up period through 28 days post-dose 4 were instructed to contact the investigator as soon as possible after rash onset for clinical evaluation and collection of clinical specimens from the lesion(s) for PCR analysis [15] .
Immunogenicity Measurements
For the evaluation of immune responses to vaccination, blood samples were collected prior to each dose of study vaccine and at 28 days post-dose 4. VZV IFN-γ ELISPOT assay was performed to directly measure the presence of IFN-γ-secreting VZV-specific peripheral blood mononuclear cells (PBMCs) before and after vaccination [16] and VZV immunoglobulin G (IgG) antibodies to VZV glycoprotein were measured by gpELISA [17] [18] [19] .
Statistical Methods
Safety Safety assessment included proportions of patients with: (1) any AE, (2) any injection-site AE, (3) any systemic AE, (4) any serious AE, (5) any vaccine-related serious AE (as determined by the blinded investigator), and (6) any discontinuation from the study due to an AE occurring after any study vaccination through 28 days post-dose 4 in each population. For these measurements, 95% CI of the risk difference between vaccine and placebo groups were examined using the asymptotic methods proposed by Miettinen and Nurminen [20] . The primary safety endpoint of the study was based on the incidence of serious AEs observed during the 4 follow-up periods in each vaccination group in each population. Two-sided 95% CIs on the proportion of patients with any serious AEs were computed, based on the exact binomial distribution [21] .
Immunogenicity
The primary immunologic endpoints were the GMFR from prevaccination to 28 days post-dose 4 of PBMC IFN-γ secretion measured by IFN-γ ELISPOT assay and of VZV antibody measured by gpELISA. The primary immunogenicity hypothesis was that ZV HT would elicit significant VZV-specific immune responses measured by either VZV IFN-γ ELISPOT or gpELISA at 28 days post-dose 4. Hypothesis testing (applicable in the HM, STM, and HIV patient populations) and estimation for each assay (VZV IFN-γ ELISPOT or gpELISA) were based on a longitudinal model [22] . Success required that the lower bound of the 90% CI for GMFR be >1.0, which is equivalent to a 1-sided P value < .05. The model only used data from the vaccine recipients, with the log-transformed VZV responses at each visit being used as response variables and the visit variable as covariate. The immunogenicity analysis was exploratory in the HCT populations because confounding treatments such as blood products might interfere with immunogenicity measures, and because clinical efficacy and immunogenicity have already been shown in this group [13, 14] .
RESULTS
Participant Accounting and Demographics
Overall, 341 patients were randomized. The ZV HT and placebo groups in each immunocompromised population were similar in terms of age, gender, race, and underlying cancer diagnosis (Table 1) . In all, 79.0% (207/262) of ZV HT recipients and 84.8% (67/79) of placebo recipients completed all study visits (Table 2) . Four (4) randomized patients who were not vaccinated are not included in the safety or immunogenicity analyses. Forty-eight (48) patients had protocol violations (some had more than 1 violation), whose immunogenicity results obtained subsequent to the violation were excluded from the immunogenicity analyses: 27 with prohibited vaccine or medication that could have interfered with immunity assessments, 13 with HZ or HZ-like rash, 9 reported exposure to VZV, and 3 did not undergo HCT (2 autologous, 1 allogeneic).
Safety
All randomized participants who received at least 1 dose of study vaccination were included in the safety analyses (Table 3 ). In the ZV HT group, the proportion of patients reporting injection site AEs ranged from 3.3% in the HIV-infected group to 36.8% in the STM group. In the placebo group, injection site reactions ranged from 0% in the allogeneic HCT group to 15.0% in the HIV-infected placebo-treated group.
In the ZV HT group, the proportion of patients reporting SAEs ranged from 12.3% for STM patients to 80.0% for allogeneic HCT patients. In the placebo group, the proportion of patients reporting SAEs ranged from 5.3% for the HM group to 70.0% for the allogeneic HCT population. Only 2 SAEs (motor sensory neuropathy [continuing at time of study discontinuation] and vomiting [resolved]), both in the HM population, were considered by the investigators to be possibly related to ZV HT .
Two patients (5%) in the ZV HT autologous HCT stratum developed auto-GVHD [23] following the first dose of the vaccine; no cases were detected in the autologous HCT placebo arm. Neither occurrence was deemed vaccine-related by the reporting investigator. GVHD occurrences were similarly distributed between the two allogeneic HCT vaccination groups (ZV HT : 21 patients [52.5%]; placebo: 5 patients [50.0%]).
Immunogenicity
Patients With STM Receiving Chemotherapy
The primary IFN-γ ELISPOT hypothesis was met in this stratum, as post-dose 4 immune responses in ZV HT recipients were significantly higher than those at baseline (GMFR = 3.0 [90% CI, 2.0-4.6], P value = < .0001; Table 4 ). Responses among ZV HT recipients were generally higher than among placebo recipients (Table 5 ).
The primary gpELISA hypothesis was also met, as post-dose 4 antibody levels measured by gpELISA were significantly higher than those at baseline (GMFR = 2.4 [90% CI, 1.8-3.0], P value < .0001; Table 4 ). Antibody levels among ZV HT recipients were generally higher than among placebo recipients postdose 4 (Table 5 ).
Patients With HM
The primary IFN-γ ELISPOT hypothesis was met in this stratum, as post-dose 4 immune responses were significantly higher among ZV HT recipients than those measured at baseline (GMFR = 2.2 [90% CI, 1.4-3.5], P value = .004; Table 4 ). Responses among those in the ZV HT group were generally higher than among placebo recipients (Table 5) .
Among ZV HT recipients, the primary gpELISA hypothesis was met, as post-dose 4 antibody levels measured by gpELISA were significantly higher than those at baseline (GMFR = 1.3 [90% CI, 1.1-1.5], P value = .003; Table 4 ). The post-dose 4 antibody levels appeared similar among the ZV HT and placebo recipients; however, baseline levels were numerically lower for the ZV HT group compared with the placebo group (Table 5) .
HIV-Infected Patients
The primary IFN-γ ELISPOT hypothesis was met, as post-dose 4 immune responses were significantly higher than those at baseline (GMFR = 1.8 [90% CI, 1.2-2.7], P value = .026; Table 4 ). Although the geometric mean concentrations (GMCs) for both the ZV HT and placebo groups were very low, responses in ZV HT group were generally higher than among placebo recipients (Table 5) .
Among ZV HT recipients in this stratum, the primary gpELISA hypothesis was met, as post-dose 4 antibody levels measured by gpELISA were significantly higher than those at baseline (GMFR = 1.4 [90% CI, 1.1-1.7], P value = .017; Table 4 ). Antibody levels were generally similar among both groups (Table 5) .
Autologous HCT Recipients
The ZV HT vaccine elicited significant VZV-specific immune responses measured by IFN-γ ELISPOT at 28 days post-dose 4 in this population (GMFR = 9.0 [90% CI, 4.4-18.4]; Table 4 ). Post-dose 4 GMCs among ZV HT recipients were generally higher than those measured in the placebo recipients (Table 5) .
Among ZV HT recipients in this stratum, VZV-specific antibody responses measured by gpELISA at 28 days post-dose 4 were not statistically significant (GMFR = 0.9 [90% CI, 0.6-1.3]; Table 4 ). Antibody levels among ZV HT recipients were generally higher than among placebo recipients post-dose 4 (Table 5) . 
VZV Infections
Two of 79 placebo patients (2.5%) and 11 of 262 vaccine patients (4.2%) presented with rashes suggestive of VZV infection during the study period and were given the diagnosis of varicella/varicella-like or HZ/HZ-like infection by a study investigator and/or primary physician (Table 6 ). PCR testing for VZV in a skin lesion was performed in lesion swabs from 8 of these 13 patients. PCR testing was ultimately positive for wild-type VZV in only 3 patients (2 placebo recipients, 1 ZV HT recipient). No patient with PCR results had a rash positive for the ZV HT strain.
DISCUSSION
The risk of reactivation of VZV, resulting in HZ, appears to inversely correlate with the level of VZV-specific cell-mediated immune responses [5, [24] [25] [26] . The greater the intensity of immunosuppression in a host, the greater the risk of HZ and attendant risk of more severe HZ presentations, including myelitis, encephalitis, or disseminated disease with visceral involvement. Profound and prolonged suppression of cell-mediated immunity occurs in individuals who are HIV-infected, have hematologic malignancies (especially those arising from the lymphatic system), are receiving long-term cytotoxic chemotherapy or immunosuppressant agents, and undergoing extensive radiation therapy. As expected, the patient groups enrolled in the present study had clear, even profound, suppression of cell-mediated immunity, as demonstrated by the observed low baseline IFN-γ ELISPOT GMCs. For context, baseline GMCs observed in this heterogeneous population of immunocompromised patients were generally lower than the baseline GMCs of immunocompetent adults observed in prior studies of the live zoster vaccine [27, 28] . Prevention and treatment of opportunistic infections, including VZV reactivation, in immunocompromised hosts remain formidable challenges and infections continue to be a major cause of morbidity and mortality in these patient populations, despite advancements in vaccines and other therapies. Live virus vaccines are typically contraindicated in immunocompromised patients due to the potential risk of unchecked replication of attenuated vaccine strains in the absence of a robust immune response. The zoster vaccine used in this study was heat-treated, which greatly limits the amount of live virus in the vaccine while preserving the quantity of viral antigen. In 2 proof-of-concept clinical trials involving both autologous HCT and allogeneic HCT recipients, there was an observed reduction in the incidence and severity of HZ among patients who received a heat-treated VZV-containing vaccine [13, 14] .
In the current study, a 4-dose regimen ZV HT was found to be generally safe in all 5 subpopulations of immunocompromised patients evaluated. Vaccine-related AEs were infrequent and consisted mostly of pain and erythema at the injection site. Two SAEs reported by 2 HM patients were deemed by the investigators to be possibly related to ZV HT . These SAEs were confounded by concurrent conditions or therapies that may have caused the SAEs. The overall incidence of all AEs and SAEs were similar for both ZV HT and placebo patients. For the HM patients, the frequencies of systemic AEs overall were increased in the vaccine group compared with the placebo group. There were no documented cases of skin lesions caused by the vaccine strain in the study.
Significant VZV-specific T-cell and antibody responses were elicited at 28 days post-dose 4 in the patients with STM, HM, and HIV infection with CD4 + counts ≤200 cells/mm 3 . Responses in all 3 of these populations met the protocol's prespecified success criteria. Immunogenicity responses observed for the STM and HM patient groups suggest that ZV HT may reduce the incidence of HZ in these groups, although clinical protection conferred by this vaccine will need to be demonstrated in a controlled clinical efficacy trial.
Immunogenicity responses elicited in HIV-infected patients were of low magnitude and may be insufficient to translate into a reduction in HZ for this patient group. In HIV-infected individuals, the frequency of HZ is greater than that of the general population at all CD4 + cell counts, moreover, the frequency increases as CD4 + cell counts decline [29] . Although HZ is not associated with increased risk of death or faster progression to AIDS, HIV-infected patients with low CD4 + counts are prone to HZ complications including ocular involvement, PHN, myelitis, meningitis, and chronic atypical skin lesions [30] . Significant VZV-specific T-cell responses were elicited at 28 days post-dose 4 in autologous HCT recipients, whereas the response elicited in allogeneic HCT recipients was poor. After HCT, reconstitution of T cells may be derived from residual recipient T cells that survived conditioning regimens, donor T cells present in the graft, and stem cells that differentiate into T cells in the recipient. Poor immunologic response to ZV HT in the allogeneic stem cell population may be related to complete or nearly complete ablation of VZV memory T cells during conditioning for allogeneic HCT and slow reconstitution of immunologically competent T cells, which may take more than a year following allogeneic transplant. [31] [32] [33] [34] . Moreover, the suppression of T-cell function is greater in allogeneic HCT compared with autologous HCT due to prolonged use of graftversus-host-disease prophylaxis with immunosuppressant agents; this may also contribute to the difference in immunogenicity of study vaccine seen between these 2 groups.
The limitations of this study included a small sample size and heterogeneous patient population and utilization of immunogenicity measures that have not been used in immunocompromised patients in previous studies. Therefore, the immunogenicity results for the HCT populations of this study cannot be directly compared to the results of earlier proof-ofconcept trials that also assessed clinical efficacy [13, 14] . In addition, although both the IFN-γ ELISPOT and gpELISA have been shown to correlate with the clinical efficacy of the live zoster vaccine in healthy, older adults, these assays may not be relevant markers of vaccine efficacy in immunocompromised populations. Nonetheless, the results of this Phase I trial of ZV HT in the immunocompromised populations examined in this study suggest a favorable safety and immunogenicity profile in certain immunocompromised populations, warranting further larger studies to evaluate the safety and efficacy of ZV HT in selected populations.
Notes
